clinical trial · NCT02542696
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Sumitomo Pharma America, Inc.·phase3·completed·n = 496
Parkinson DiseaseAPL-130277
brief summary
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
started
Aug 31, 2015
primary completion
Nov 8, 2022
completion
Nov 8, 2022
last updated
Nov 22, 2023
official title
An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol